Insulin Lispro Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Insulin Lispro Supply in 2026

Insulin Lispro remains one of the most widely prescribed rapid-acting insulin analogs in the United States, with millions of patients depending on it for prandial glucose control. Over the past two years, supply disruptions have required prescribers to navigate formulary shifts, counsel patients on product substitutions, and, in some cases, transition patients to alternative rapid-acting insulins.

This article provides an up-to-date overview of the Insulin Lispro shortage situation, its prescribing implications, and practical tools to help you support your patients in 2026.

Timeline: How We Got Here

2023: Historic Price Reductions

In March 2023, Eli Lilly announced a 70% reduction in the list price of Humalog and introduced an authorized generic Insulin Lispro vial at a list price of just $25. The Lilly Insulin Value Program was expanded to cap patient out-of-pocket costs at $35/month regardless of insurance status. While transformative for patient access, these changes triggered a significant demand surge that strained manufacturing and distribution capacity.

2024: Supply Disruptions Emerge

By mid-2024, Eli Lilly began reporting supply limitations for certain Insulin Lispro products. Increased demand, coupled with manufacturing line transitions, resulted in intermittent shortages of specific NDCs. The ASHP added several Insulin Lispro formulations to its drug shortage database.

2025: Product Discontinuations and Global Factors

In October 2025, Lilly officially discontinued the 3 mL vial presentations of Insulin Lispro as a business decision. Concurrently, Sanofi reported supply constraints for Admelog/Insulin Lispro Sanofi affecting European and EEA markets beginning Q1 2026, signaling ongoing global manufacturing capacity challenges for rapid-acting insulin analogs.

2026: Current State

The supply picture has improved for most common presentations. The 10 mL vials and KwikPen products are generally available, though regional variations persist. Specific NDCs tracked by ASHP may remain in limited supply. Admelog availability is inconsistent in some markets.

Prescribing Implications

Formulary Considerations

The interplay between payer formularies and product availability creates a complex landscape for prescribers. Key considerations include:

• Generic Insulin Lispro is now on Tier 2-3 of most commercial formularies and is the most cost-effective option for patients
• Humalog (brand) may require prior authorization on some plans, though it remains widely covered
• Admelog coverage varies — check patient-specific formulary status before prescribing, especially given supply concerns
• Lyumjev (insulin lispro-aabc) is an ultra-rapid alternative covered by the Lilly Insulin Value Program; may be an option when standard lispro is unavailable

Switching Between Products

When transitioning patients between Insulin Lispro formulations or brands:

• Humalog ↔ Generic Insulin Lispro ↔ Admelog: These contain the same active ingredient and are generally interchangeable at a 1:1 unit ratio. Pharmacy-level substitution is often permissible, but verify with state-specific regulations for biologics/biosimilar substitution.
• Insulin Lispro → Lyumjev: Lyumjev has a faster onset due to added treprostinil and citrate. While the core molecule is the same, the different pharmacokinetic profile may require patient education and closer monitoring during transition. A new prescription is required.
• Insulin Lispro → Insulin Aspart or Glulisine: These are therapeutically equivalent rapid-acting analogs. Unit-for-unit conversion is standard, but recommend increased blood glucose monitoring for 1-2 weeks post-switch.

Documentation and Prior Authorization

If a patient's formulary-preferred insulin is unavailable due to shortage, most payers have expedited exception processes. Document the shortage as the clinical rationale for the formulary exception. ASHP shortage notices and FDA shortage listings serve as supporting evidence.

Current Availability Picture

ProductStatus (March 2026)NotesInsulin Lispro 100 units/mL, 10 mL vial (generic)Generally availableList price $25/vialInsulin Lispro KwikPen 100 units/mL, 5-packGenerally availableSome NDCs intermittently limitedInsulin Lispro 3 mL vialDiscontinuedDiscontinued October 2025Humalog 100 units/mL, 10 mL vialAvailable70% price reduction effectiveHumalog KwikPen 100 units/mLAvailableHumalog U-200 KwikPenAvailableAdmelog 100 units/mLIntermittentEU/EEA shortages reported Q1 2026Lyumjev 100 units/mLAvailableCovered by Lilly Insulin Value Program

Cost and Access Landscape

Key Pricing Points for 2026

• Medicare Part D: $35/month copay cap per insulin (Inflation Reduction Act)
• Lilly Insulin Value Program: $35/month for all Lilly insulins (commercial and uninsured)
• Generic Insulin Lispro vial: $25 list price
• Lilly Cares Patient Assistance Program: Free insulin for qualifying uninsured/underinsured patients (≤400% FPL)

Patient Assistance Resources

For patients experiencing financial barriers:

• Lilly Insulin Value Program: insulins.lilly.com — savings card for $35/month
• Lilly Cares: lillycares.com — free insulin for qualifying patients
• NeedyMeds: needymeds.org — database of assistance programs
• RxAssist: rxassist.org — comprehensive PAP database

Tools and Resources for Your Practice

Real-Time Stock Checking

Medfinder for Providers enables clinicians and care teams to check real-time pharmacy availability of Insulin Lispro and other medications. This can be particularly valuable during shortage periods, allowing you to direct patients to pharmacies that currently have stock rather than sending them on a frustrating search.

Shortage Monitoring

• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — tracks specific NDC-level shortages
• FDA Drug Shortages Database: accessdata.fda.gov/scripts/drugshortages — official FDA shortage notices
• Drugs.com Shortage Page: drugs.com/drug-shortages — patient-friendly shortage updates

Patient Education Materials

Consider sharing these resources with patients who are affected by the shortage:

• Insulin Lispro shortage update for patients
• How to find Insulin Lispro in stock
• How to save money on Insulin Lispro

Looking Ahead

The insulin supply landscape continues to evolve. Key developments to monitor in 2026 include:

• Additional biosimilar approvals that may further expand the rapid-acting insulin supply
• Potential extension of the $35 copay cap to commercial insurance at the federal level
• Sanofi's Admelog manufacturing recovery timeline — updates expected mid-2026
• Ongoing generic competition driving continued price reductions

Final Thoughts

The Insulin Lispro shortage has required prescribers to be more proactive about supply monitoring, formulary navigation, and patient counseling. While the situation has improved materially since 2024, complete resolution remains a work in progress — particularly for less common formulations and in underserved regions.

Leveraging tools like Medfinder for Providers, staying current on ASHP shortage updates, and maintaining familiarity with therapeutic alternatives positions your practice to minimize disruption for the patients who depend on this essential medication.

For additional provider-focused guidance on helping patients navigate insulin access, see our companion article: How to help your patients find Insulin Lispro in stock.